{
    "nctId": "NCT06230185",
    "briefTitle": "ctDNA Based MRD Testing for NAC Monitoring in TNBC",
    "officialTitle": "Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients With Early Stage TNBC-Phase I (B-STRONGER-I)",
    "overallStatus": "RECRUITING",
    "conditions": "TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 422,
    "primaryOutcomeMeasure": "Evaluate the correlation of MRD to pCR after NAC in TNBC",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Have histologically documented TNBC (defined as ER expression \u226410% by IHC, PR expression\u226410% by IHC and HER2 0 or 1+ by IHC or FISH ratio \\<2 or HER2 gene copy number of \\<6).\n2. Early-stage breast cancer (stage I-III) and scheduled to undergo NAC treatment with curative intent.\n3. Be informed of the investigational nature of the study and all pertinent aspects of the trial.\n4. Have the ability to understand and the willingness to sign a written informed consent document in accordance with institutional and federal guidelines.\n5. Be \u2265 18years of age.\n6. Patient who are scheduled to start NAC.\n7. Be willing to provide blood samples before and during treatment.\n8. Have available biopsy tissue.\n\nExclusion Criteria:\n\n1. Receiving concurrent anti-neoplastic therapy for another malignancy.\n2. Stage IV disease.\n3. Current or history of another primary cancer within 5 years of study entry, with the exception of basal or squamous cell skin cancer, or non-invasive malignancy.\n4. History of allogeneic bone marrow or organ transplant.\n5. Blood transfusion within two weeks before collection of blood for central ctDNA testing.\n6. Started systemic therapy for their breast cancer.\n7. Pregnancy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}